AXA Investment Managers’s Supernus Pharmaceuticals SUPN Stock Holding History

AXA Investment Managers’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$619K	Buy	+12,957	New	+$522K	﹤0.01%	960

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AXA Investment Managers's SUPN Position: Q3 2025 in Review

AXA Investment Managers opened a new position in Supernus Pharmaceuticals (SUPN) in Q3 2025: 12,957 shares worth $619K. The stake represents ﹤0.01% of the portfolio and ranks #960 among its holdings.

310 funds tracked by Wall St. Rank hold SUPN as of Q3 2025.

AXA Investment Managers held 12,957 shares of Supernus Pharmaceuticals worth $619K as of Q3 2025.
Supernus Pharmaceuticals was a new AXA Investment Managers position in Q3 2025.
Supernus Pharmaceuticals made up ﹤0.01% of AXA Investment Managers's portfolio in Q3 2025, its #960 holding.
310 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2025.

Based on AXA Investment Managers's 13F filing for Q3 2025, filed 14 Nov 2025.